Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials

Critical Reviews in Oncology/Hematology

Volumn 97, Issue , 2016, Pages 65-71

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Gastric cancer; Immune checkpoints; PD 1; PD L1; Pembrolizumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COLITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTRIC CARCINOGENESIS; HEPATITIS; HUMAN; HYPOPHYSITIS; NONHUMAN; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; THYROIDITIS; TUMOR IMMUNOLOGY; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CTLA-4 ANTIGEN; HUMANS; IMMUNE SYSTEM PHENOMENA; IMMUNOTHERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84952639687     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.08.015     Document Type: Review

References (54)

1. Abdel-Rahman O. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev. Anticancer Ther. 2014, 1-11.
2. Abdel-Rahman O. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. Tumor Biol. 2014, 1-11.
3. Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med. Oncol. 2015, 32(1):431. Epub 2014 Dec 9. 10.1007/s12032-014-0431-8.
4. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit. Rev. Oncol. Hematol. 2015, 93(1):18-27.
5. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8:765-772.
6. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
7. Alegre M.L., Noel P.J., Eisfelder B.J., Chuang E., Clark M.R., Reiner S.L., et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 1996, 157:4762-4770.
8. Antonia S.J., Larkin J., Ascierto P.A. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin. Cancer Res. 2014, 20(24):6258-6268.
9. Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31(33):4199-4206.
10. Berger R., Rotem-Yehudar R., Slama G., et al. Phase I. safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14(10):3044-3051.
11. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366(26):2455-2465.
12. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
13. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular characterization of gastric adenocarcinoma, Nature.
14. Das S., Suarez G., Beswick E.J., Sierra J.C., Graham D.Y., Reyes V.E. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 2006, 176(5):3000-3009.
15. Fanos K.S., Bruno T.C., Meeker A.K., De Marzo A.M., Isaacs W.B., Drake C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69:1694-1703.
16. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 2012, 23:viii6-9.
17. Fitzgerald R., Hardwick R., Huntsman D. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J. Med. Genet. 2010, 47:436-444.
18. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192(7):1027-1034.
19. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369(2):134-144.
20. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
21. Hou R., Cao B., Chen Z., Li Y., Ning T., Li C., et al. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol. Biol. Rep. 2010, 37(1):515-520.
22. Hou J., Yu Z., Xiang R., Li C., Wang L., Chen S., et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp. Mol. Pathol. 2014, 96(3):284-291.
23. Insley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991, 174:561-569.
24. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 2013, 94(1):25-39.
25. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
26. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
27. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
28. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012, 72:3125-3130.
29. Kim J.W., Nam K.H., Ahn S.H., Park D.J., Kim H.H., Kim S.H., et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 2014, 1-11.
30. Kordes S., Cats A., Meijer S.L., van Laarhoven H.W. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit. Rev. Oncol. Hematol. 2014, 90:68-76.
31. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
32. Liu S.M., Meng Q., Zhang Q.X., Wang S.D., Liu Z.J., Zhang X.F. Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma. Zhonghua zhong liu za zhi [Chin. J. Oncol.] 2008, 30(3):192-195.
33. Lu B., Chen L., Liu L., Zhu Y., Wu C., Jiang J., Zhang X. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol. Res. 2011, 50(2-3):269-275.
34. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012, 30:2046-2054.
35. Miyatake S., Nakaseko C., Umemori H., Yamamoto T., Saito T. Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD152). Biochem. Biophys. Res. Commun. 1998, 249:444-448.
36. Momtaz P., Postow M.A. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics Pers. Med. 2014, 7:357.
37. Muro K., Bang Y., Shankaran V., Geva R., Catenacci D.V.T., Gupta S., Chung H.C. LBA15A phase 1B study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancer. Ann. Oncol. 2014, 25(Suppl. 4). mdu438-15.
38. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 2:252-264.
39. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
40. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 2008, 224:141-165.
41. Ralph C., Elkord E., Burt D.J., O'Dwyer J.F., Austin E.B., Stern P.L., et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin. Cancer Res. 2010, 16(5):1662-1672.
42. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
43. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364(26):2517-2526.
44. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J.W., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
45. Saito H., Kuroda H., Matsunaga T., Osaki T., Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J. Surg. Oncol. 2013, 107(5):517-522.
46. Savabkar S., Azimzadeh P., Chaleshi V., Mojarad E.N., Aghdaei H.A. Programmed death-1 gene polymorphism (PD-1. 5C/T) is associated with gastric cancer. Gastroenterol. Hepatol. Bed Bench 2013, 6(4):178.
47. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
48. Wang W., Li F., Mao Y., Zhou H., Sun J., Li R., et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum. Genet. 2013, 132(6):641-648.
49. Westin J.R., Chu F., Zhang M., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet. Oncol. 2014, 15(1):69-77.
50. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369(2):122-133.
51. Wolchok J., Kluger H.M., Callahan M.K., Postow M.A., Gordon R.A., Segal N.H., et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). J. Clin. Oncol. 2013, 31(Suppl. abstr 9012).
52. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006, 108(1):19-24.
53. Zheng Z., Bu Z., Liu X., Zhang L., Li Z., Wu A., et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin. J. Cancer Res. 2014, 26(1):104.
54. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8:467-477.